3/18
04:00 pm
alt
Altimmune (ALT) is now covered by Truist Financial Corporation. They set a "buy" rating and a $12.00 price target on the stock.
Neutral
Report
Altimmune (ALT) is now covered by Truist Financial Corporation. They set a "buy" rating and a $12.00 price target on the stock.
3/16
12:23 pm
alt
Altimmune (ALT) had its price target raised by HC Wainwright from $12.00 to $25.00. They now have a "buy" rating on the stock.
Low
Report
Altimmune (ALT) had its price target raised by HC Wainwright from $12.00 to $25.00. They now have a "buy" rating on the stock.
3/12
12:02 pm
alt
Altimmune Touts Pemvidutide Progress, Targets MASH Phase 3 Start and Q3 AUD Readout at Barclays Chat [Yahoo! Finance]
Low
Report
Altimmune Touts Pemvidutide Progress, Targets MASH Phase 3 Start and Q3 AUD Readout at Barclays Chat [Yahoo! Finance]
3/11
07:58 pm
alt
Altimmune Details Pemvidutide MASH Path: Breakthrough Therapy, FDA Feedback, Phase 3 Next Up [Yahoo! Finance]
Medium
Report
Altimmune Details Pemvidutide MASH Path: Breakthrough Therapy, FDA Feedback, Phase 3 Next Up [Yahoo! Finance]
3/6
11:34 am
alt
Altimmune (ALT) had its price target lowered by B. Riley Financial, Inc. from $18.00 to $13.00. They now have a "buy" rating on the stock.
Medium
Report
Altimmune (ALT) had its price target lowered by B. Riley Financial, Inc. from $18.00 to $13.00. They now have a "buy" rating on the stock.
3/6
08:40 am
alt
Altimmune Reports FY25 Financials: Why Is Big Pharma Staying Away [Seeking Alpha]
Low
Report
Altimmune Reports FY25 Financials: Why Is Big Pharma Staying Away [Seeking Alpha]
3/5
04:33 pm
alt
Altimmune Inc (ALT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Fortification [Yahoo! Finance]
Low
Report
Altimmune Inc (ALT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Fortification [Yahoo! Finance]
3/5
01:08 pm
alt
Altimmune (ALT) had its "market perform" rating reaffirmed by William Blair.
Medium
Report
Altimmune (ALT) had its "market perform" rating reaffirmed by William Blair.
3/5
07:41 am
alt
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates [Yahoo! Finance]
High
Report
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates [Yahoo! Finance]
3/5
07:00 am
alt
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
High
Report
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
3/2
07:30 am
alt
Altimmune to Participate in Upcoming Investor Conferences
Low
Report
Altimmune to Participate in Upcoming Investor Conferences
2/26
07:30 am
alt
Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
Low
Report
Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
2/17
09:02 pm
alt
Altimmune, Inc. (ALT) Gains Analyst Support as Pemvidutide Advances [Yahoo! Finance]
Low
Report
Altimmune, Inc. (ALT) Gains Analyst Support as Pemvidutide Advances [Yahoo! Finance]
2/3
03:55 pm
alt
Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 [Seeking Alpha]
Neutral
Report
Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 [Seeking Alpha]
2/2
10:02 am
alt
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development [Yahoo! Finance]
Low
Report
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development [Yahoo! Finance]
1/29
05:54 pm
alt
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
Medium
Report
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
1/29
01:31 pm
alt
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
Low
Report
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
1/29
07:41 am
alt
Altimmune (NASDAQ:ALT) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
Altimmune (NASDAQ:ALT) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
1/27
09:25 pm
alt
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
High
Report
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
1/27
06:00 pm
alt
Altimmune (NASDAQ:ALT) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
High
Report
Altimmune (NASDAQ:ALT) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
1/5
07:54 am
alt
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH [Yahoo! Finance]
Low
Report
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH [Yahoo! Finance]
1/5
07:30 am
alt
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
Medium
Report
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
12/19
07:02 am
alt
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial [Yahoo! Finance]
High
Report
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial [Yahoo! Finance]
12/19
06:30 am
alt
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial
High
Report
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial